| Metric | Q3 FY26 | Q2 FY26 | Q3 FY25 |
|---|---|---|---|
| Other income | 206.0 | 269.0 | 222.0 |
| Total income | 7281.0 | 7858.0 | 7295.0 |
| Exceptional items | -276.0 | 0.0 | 0.0 |
| Net profit | 674.0 | 1353.0 | 1575.0 |
| Operating margin | 12.3% | 23.6% | 26.3% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -57.20% |
|---|---|
| Net profit, quarter on quarter | -50.20% |
BSE results filing, NSE: CIPLA. Figures extracted from the filing.
Cipla Ltd: key numbers
- Share price
- ₹1,361.20
- Market cap
- ₹1,09,967 Cr
- Revenue (annual)
- ₹28,163 Cr
- Net profit (annual)
- ₹3,879 Cr
- P/E (TTM)
- 32.6×Sector 49.8×
- Promoter holding
- 29.21%+0.00% QoQ
- FII holding
- 20.20%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Cipla Ltd
All →Cipla Employee Stock Options
Cipla allotted 12,168 equity shares following the exercise of options under its ESOS and ESAR schemes. This increases the company's total paid-up share capital.
Cipla Management Change
Cipla Ltd announced that Mr. Venkata Sai Mungara has transitioned to a subsidiary role, ceasing to be a Senior Management Personnel effective October 1, 2026.
Cipla Other Announcement
Cipla announced it was assigned an ESG rating of 68 by Niche Ninety Nine Capability and Certifications (OPC) Private Limited, a SEBI-registered rating provider.
Cipla Acquisition
Cipla is notifying shareholders and creditors about a Scheme of Amalgamation with Inzpera Healthsciences, providing them an opportunity to submit representations to the NCLT.
Cipla Partnership
Cipla signed an exclusive licensing and supply agreement with SBP Group’s CTTQ for the drug Rolditamig Deuderuxtecan. This collaboration aims to accelerate therapy access in licensed markets.
Cipla Merger & Restructuring
Cipla Ltd. announced an internal restructuring where Aspergen Limited, India, acquired a 100% stake in Aspergen Inc., USA, from existing group subsidiaries.